Advertisement
Singapore markets closed
  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     
  • S&P 500

    5,079.06
    +8.51 (+0.17%)
     
  • Dow

    38,473.74
    -29.95 (-0.08%)
     
  • Nasdaq

    15,786.14
    +89.50 (+0.57%)
     
  • Bitcoin USD

    65,443.74
    -1,335.87 (-2.00%)
     
  • CMC Crypto 200

    1,426.65
    +2.55 (+0.18%)
     
  • FTSE 100

    8,050.96
    +6.15 (+0.08%)
     
  • Gold

    2,334.70
    -7.40 (-0.32%)
     
  • Crude Oil

    82.92
    -0.44 (-0.53%)
     
  • 10-Yr Bond

    4.6640
    +0.0660 (+1.44%)
     
  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     
  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     
  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Capri, Abercrombie tumble; Marvell Technology rises

Capri, Abercrombie tumble; Marvell Technology rises

NEW YORK (AP) -- Stocks that moved substantially or traded heavily on Wednesday:

Abercrombie & Fitch Co., down $6.62 to $18.39

The clothing and accessories retailer reported disappointing results and a weak outlook for a key sales measure.

Capri Holdings Ltd., down $3.83 to $35.06

The owner of Michael Kors and Versace brands gave investors a weak revenue forecast for fiscal 2020.

Cypress Semiconductor Corp., up $1.85 to $17.25

The chipmaker is considering a sale after receiving a takeover offer, according to media reports.

Canada Goose Holdings Inc., down $15.13 to $33.89

The luxury coat maker issued a weak revenue forecast for the fiscal year.

ADVERTISEMENT

Cara Therapeutics Inc., up $3.59 to $21.57

The drug developer reported solid study results for a drug aimed at dialysis-related itchiness.

Marvell Technology Group Ltd., up 67 cents to $22.02

NXP Semiconductors is buying the company's wireless connectivity business for $1.76 billion in cash.

ArcelorMittal SA, down 35 cents to $15.35

The world's largest steelmaker announced further cuts to production at several plants in Europe due to weak demand and high imports.

Johnson & Johnson, down $5.74 to $131.33

The health products giant faces the second day of a high profile trial in Oklahoma focusing on its role in the opioid crisis.